XOMA (XOMA Royalty) Long-Term Debt : $108.09 Mil (As of Sep. 2024)

View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Long-Term Debt?

XOMA Royalty's Long-Term Debt for the quarter that ended in Sep. 2024 was $108.09 Mil.

XOMA Royalty's quarterly Long-Term Debt increased from Mar. 2024 ($114.53 Mil) to Jun. 2024 ($115.08 Mil) but then declined from Jun. 2024 ($115.08 Mil) to Sep. 2024 ($108.09 Mil).

XOMA Royalty's annual Long-Term Debt stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($118.52 Mil).

XOMA Royalty Long-Term Debt Historical Data

The historical data trend for XOMA Royalty's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Long-Term Debt Chart

XOMA Royalty Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

27.09

12.76

118.52

XOMA Royalty Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															-	118.52	114.53	115.08	108.09

XOMA Royalty (NAS:XOMA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

XOMA Royalty Long-Term Debt Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMA) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA 0M26:UK X0M1:Germany X0M1:Germany

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Executives

Thomas M. Burns	officer: Chief Financial Officer	2910 SEVENTH STREET, BERKELEY CA 94710
Owen Hughes	director, officer: Interim CEO	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Bradley Sitko	officer: Chief Investment Officer	C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
James R Neal	officer: VP Business Development	2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday	director	932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman	director	C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz	director	3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta	officer: Chief Business Officer	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian	director, officer: Director and CEO	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry	director, other: See Explanation of Responses	ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104